Phase 1Completed

Bioequivalence Study of of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma, Egypt) and Janumet 50/1000 mg F.C.Tablets (Merck Sharp & Dohme, The Netherlands)

Comparative, Randomized, Single Dose, Two-way Crossover Bioequivalence Study to Determine the Bioequivalence of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma for Pharmaceuticals & Medical Appliances, Egypt) and Janumet 50/1000 mg F.C.Tablets (Merck Sharp & Dohme, The Netherlands) After a Single Oral Dose Administration of Each to Healthy Adults Under Fed Conditions.

Sponsor

Genuine Research Center, Egypt (Industry)

Enrollment

30 enrolled

Conditions

Healthy

Interventions

Gleptomet 50/1000(Metformin HCl & Sitagliptin); Janumet 50/1000(Metformin HCl & Sitagliptin)

Ages

adults

Registry

NCT05798715

Full record on ClinicalTrials.gov